From: Assessment of health-related quality of life in patients receiving stem cell therapy for end-stage liver disease: an Egyptian study
SF-v2
P value SCT group (I) versus
healthy volunteers group (III)
SMT group II
PF
0.00
0.04
RP
0.001
BP
0.19
GH
0.81
VT
0.14
SF
0.01
RE
MH
0.28
PCS
0.17
MCS
0.004